TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue
Suite 1608
New York, NY 10022
United States
212-980-9155
http://www.tonixpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Seth LedermanCo-Founder, Pres, CEO & Chairman632.5kN/A1958
Mr. Bradley SaengerCFO & Treasurer405kN/A1974
Dr. Gregory M. SullivanChief Medical Officer & Sec.405kN/A1966
Mrs. Jessica Edgar MorrisChief Operating OfficerN/AN/AN/A
Dr. Ronald R. Notvest Ph.D., MBAExec. VP of Commercial Planning and Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for the prevention and treatment of organ transplant rejection. The company was founded in 2007 and is based in New York, New York.

Corporate Governance

Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.